Loading clinical trials...
Loading clinical trials...
A Prospective, Randomized Clinical Study of Safety and Efficacy by Using Docetaxel With or Without Traditional Chinese Medicine XH1 in Patients With Stage ⅢB-Ⅳ Non-small Cell Lung Cancer (NSCLC) Who Failed With First-line Chemotherapy
Conditions
Interventions
Docetaxel
Chinese traditional medicine XH1
Locations
1
China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Start Date
February 1, 2018
Primary Completion Date
February 1, 2019
Completion Date
February 1, 2019
Last Updated
September 13, 2018
NCT06305754
NCT05920356
NCT06128551
NCT07251582
NCT01720836
NCT06567015
Lead Sponsor
Haining Health-Coming Biotech Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions